CRDF on Nasdaq
Cardiff Oncology, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Lexeo Therapeutics, Inc., ImageneBio, Inc. or Compass Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-8256.3%Operating margin3
-7732.0%Net margin3
-13.2%Revenue growth, 20253
-101.0%Return on equity3
-$38.0MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Selling, general and admin100¢$14.2M
Out of $593.0K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Royalty revenues | $593.0K | $683.0K |
| Research and development | $35.3M | $36.9M |
| Selling, general and administrative | $14.2M | $12.5M |
| Total operating expenses | $49.6M | $49.3M |
| Loss from operations | -$49.0M | -$48.7M |
| Interest income | $3.1M | $3.3M |
| Other income (expense), net | $5.0K | -$39.0K |
| Total other income (expense), net | $3.1M | $3.2M |
| Net loss | -$45.9M | -$45.4M |
| Preferred stock dividend payable on Series A Convertible Preferred Stock | -$25.0K | -$24.0K |
| Net loss attributable to common stockholders | -$45.9M | -$45.5M |
| Net loss per common share - basic | -$0.69 | -$0.95 |
| Net loss per common share - diluted | -$0.69 | -$0.95 |
| Weighted-average shares outstanding - basic | 66.8M shares | 47.6M shares |
| Weighted-average shares outstanding - diluted | 66.8M shares | 47.6M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $17.5M | $51.5M | |
| Short-term investments | $40.8M | $40.3M | |
| Accounts receivable and unbilled receivable | $182.0K | $773.0K | |
| Prepaid expenses and other current assets | $1.6M | $2.5M | |
| Total current assets | $60.1M | $95.1M | |
| Property and equipment, net | $578.0K | $898.0K | |
| Operating lease right-of-use assets | $629.0K | $1.2M | |
| Other assets | $549.0K | $69.0K | |
| Total Assets | $61.9M | $97.2M | |
| Accounts payable | $8.1M | $4.8M | |
| Accrued liabilities | $7.6M | $7.9M | |
| Operating lease liabilities | $730.0K | $710.0K | |
| Total current liabilities | $16.4M | $13.4M | |
| Operating lease liabilities, net of current portion | $102.0K | $813.0K | |
| Total Liabilities | $16.5M | $14.2M | |
| Preferred stock, $0.001 par value, 20,000 shares authorized; 277 designated as Series A Convertible Preferred Stock; 61 shares outstanding at December 31, 2025 and December 31, 2024 with liquidation preference of $1,117 and $1,092 at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock, $0.0001 par value, 150,000 shares authorized; 68,305 and 66,524 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $7.0K | $7.0K | |
| Additional paid-in capital | $475.4M | $467.1M | |
| Accumulated other comprehensive gain | $50.0K | $34.0K | |
| Accumulated deficit | -$430.0M | -$384.2M | |
| Total stockholders equity | $45.4M | $82.9M | $69.7M |
| Total liabilities and stockholders equity | $61.9M | $97.2M | |
| Preferred Stock, par value (in USD per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 20.0M shares | 20.0M shares | |
| Temporary equity, shares authorized (in shares) | 277.0K shares | 277.0K shares | |
| Temporary equity, shares outstanding (in shares) | 61.0K shares | 61.0K shares | |
| Preferred stock, liquidation preference, value | $1.1M | $1.1M | |
| Common stock, par value (in USD per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 150.0M shares | 150.0M shares | |
| Common stock, shares issued (in shares) | 68.3M shares | 66.5M shares | |
| Common stock, shares outstanding (in shares) | 68.3M shares | 66.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$45.9M | -$45.4M |
| Depreciation | $364.0K | $404.0K |
| Stock-based compensation expense | $5.7M | $4.8M |
| Amortization of right-of-use assets | $540.0K | $539.0K |
| Accretion of discounts on short-term investments, net | -$848.0K | -$598.0K |
| Accounts receivable and unbilled receivable | $591.0K | -$484.0K |
| Prepaid expenses and other current assets | $557.0K | -$452.0K |
| Other assets | -$480.0K | $1.2M |
| Accounts payable and accrued liabilities | $2.2M | $3.0M |
| Operating lease liabilities | -$691.0K | -$626.0K |
| Net cash used in operating activities | -$37.9M | -$37.7M |
| Capital expenditures | -$44.0K | -$80.0K |
| Maturities of short-term investments | $71.1M | $27.1M |
| Purchases of short-term investments | -$71.9M | -$23.6M |
| Sales of short-term investments | $2.1M | $10.3M |
| Net cash provided by investing activities | $1.3M | $13.7M |
| Proceeds from sales of common stock, net of expenses of $0 and $3,286, respectively | $0 | $53.4M |
| Proceeds from exercise of warrants, net of expense of $169 and $0, respectively | $2.1M | $0 |
| Proceeds from exercise of options | $493.0K | $373.0K |
| Net cash provided by financing activities | $2.6M | $53.8M |
| Net change in cash and cash equivalents | -$34.0M | $29.8M |
| Cash paid for taxes | $1.0K | $1.0K |
| Purchases of unsettled short-term investments included in accrued liabilities | $744.0K | $0 |
| Stock issuance expenses | $0 | $3.3M |
| Exercise of warrants | $169.0K | $0 |
Former names
Recent filings
- Sep 14, 20268-K
- Aug 26, 2026DEF 14A
- Aug 26, 2026DEFA14A
- Aug 14, 2026PRE 14A
- Aug 11, 202610-Q
- Aug 11, 20268-K
- Jul 27, 2026SCHEDULE 13G/A
- Jul 21, 2026S-8
- Jul 16, 2026424B5
- Jul 16, 20268-K
- Jul 16, 20264
- Jul 16, 20264
- Jun 22, 20264
- Jun 22, 20264
- Jun 15, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10